Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

By D. Rog, T. Nurmikko, T. Friede, C. Young. Neurology, 2005

672 citations recorded by the source corpus.

Subfields: Neurology, Pharmacology, Sensory Systems

View Paper: https://www.semanticscholar.org/paper/dd130172df889979afc3b5e30b7665cf0accb8cb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

1. N. Finnerup
2. T. S. Jensen

In Pharmacology

1. T. S. Jensen
2. S. Sindrup
3. P. Pacher
4. S. Batkai
5. George Kunos
6. N. Finnerup

Citations in the corpus

• The evidence for pharmacological treatment of neuropathic pain (2010, background): “Cannabinoids have a modest effect on central pain in multiple sclerosis [79,101].”
• Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, background): “These include cannabinoids, neuropeptides and ion channels, which are present and subject to modulation also in the immune system, and some neurotransmitters such as dopamine (Rog et al., 2005; Nessler et al., 2006; Vollmar et al., 2009).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “Sativex was well tolerated and effective against central neuropathic pain and sleep disturbances associated with MS in a randomized, controlled trial involving 66 patients (Rog et al., 2005).”